Prem Subramanian, MD, PhD, Professor of Ophthalmology at the University of Colorado School of Medicine, discusses long-term data testing teprotumumab in patients with thyroid eye disease (TED).
TED is a rare autoimmune disease that can dramatically impact a person’s vision. The condition often occurs in people with hyperthyroidism or Graves’ disease (GD). However, it can also occur in association with hypothyroidism, euthyroidism, and Hashimoto’s thyroiditis. GD affects approximately 1% to 2% of the adult population, with an estimated 40% of GD patients subsequently developing TED over the course of their lifetime. The onset of TED typically occurs between 30 and 50 years of age, with the disease course more severe after age 50. Common symptoms can include upper eyelid retraction, dry eyes, inflammation, light sensitivity, as well as the sensation of a foreign body present in the eye.
Current management of the disease generally starts with control of the underlying thyroid issue. Endocrinologists and ophthalmologists then work together to determine which combination of medical or surgical interventions may benefit the patient.
Tepezza (teprotumumab-trbw) is an insulin-like growth factor 1 receptor (IGF-1R) inhibitor. It is administered as an intravenous infusion.
Post Hoc Analysis
A post-hoc analysis was conducted to assess the long-term efficacy of teprotumumab. 112 patients received eight infusions of the treatment in a phase 2, phase 3, and phase 3 extension study. 82% percent of patients within these studies reported no need for additional TED treatment after two years post-treatment with teprotumumab. After week 72, 89.5% of patients maintained response for composite outcome, 91.2% in clinical activity score, 72.9% in diplopia, 67.9% in proptosis, and 66.1% in overall response. Additionally, adverse events were maintained consistent with the previous safety profile. New cases of hyperglycemia and hearing impairment were reported.
For more information, click here.
To learn more about TED and other rare ophthalmology diseases, visit https://checkrare.com/diseases/ophthalmology-eye-diseases/
